China SXT Pharmaceuticals, Inc. (SXTC) 주식 — 좋은 사업일까?

China SXT Pharmaceuticals, Inc. (SXTC) 주식 — 좋은 사업일까? — InspectStocks

Keep exploring

The themes China SXT Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Drug Manufacturers Specialty and Generic

Graded A or B and worth $2B or more: A first, then the largest.

All 78 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

어떻게 돈을 버는가

Regular traditional Chinese medicine pieces95%
Advanced traditional Chinese medicine pieces4%

매출 비중은 year ended March 31, 2026 기준 추정치이며, 제출된 보고서의 수치가 아닙니다.

경쟁 상대

600518Kangmei Pharmaceutical Co., Ltd.
300147Xiangxue Pharmaceutical Co., Ltd.

무엇을 파는가6

Regular traditional Chinese medicine pieces
Medicinal plants processed into forms such as cut pieces or powders, generally prepared by boiling or decoction before use.
Directly-Oral advanced TCMP
Processed herbal medicines made to be taken by mouth without first being boiled as a decoction.
After-Soaking-Oral advanced TCMP
Small sealed bags of herbal material steeped in hot water to make an infusion.

3개 더 보기

SanQiFen
A directly swallowed powder made from the roots and rhizomes of notoginseng.
CuYanHuSuo
A directly swallowed powder made from the tubers of Corydalis yanhusuo.
LuXueJing
A directly swallowed product made from dried deer blood.

누가 사는가3

Hospitals, especially traditional Chinese medicine hospitals, buy products for patient care, mainly in Jiangsu province.
Pharmaceutical wholesalers buy products and distribute them to hospitals and other healthcare distributors.
As of March 31, 2026, end customers included 46 pharmaceutical companies, 11 chain pharmacies and 12 hospitals (March 31, 2026, high).

무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가

사업이 기대고 있는 것

1Relies on medicinal-plant raw materials supplied by vendors in China.
2Relies on a limited number of customers; hospitals and pharmaceutical distributors account for important sales channels.
3Its business in China depends on contractual arrangements with Taizhou Suxuantang, a variable interest entity, rather than direct ownership of that operating company.

잘못될 수 있는 일

1Losing or reducing sales to a small number of major customers could harm revenue.
2Disruptions in the supply of medicinal plants or other raw materials could interrupt production and deliveries.
3The company may be unable to enforce its contractual arrangements with Taizhou Suxuantang, or changes in Chinese rules may affect those arrangements or its ability to operate.

전체 재무제표 보기 →

China SXT Pharmaceuticals, Inc. 소개

China SXT makes traditional Chinese medicine pieces (TCMP) from medicinal plants, including herbs prepared as powders and other forms. In the fiscal year ended March 31, 2026, regular TCMP made up 95.02% of revenue (FY2026, high), while advanced TCMP made up 4.35% (FY2026, high); some advanced products can be swallowed directly or steeped in hot water. Total revenue was $1,138,052 (year ended March 31, 2026, high).

본사: Taizhou, Jiangsu, China
설립: 2017
임직원 수: 56 full-time employees (March 31, 2026, high)
상장 시장: Nasdaq Capital Market
회계연도 종료: March 31

China SXT Pharmaceuticals, Inc.이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.

Keep exploring

The themes China SXT Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.